Nadav Kidron, Oramed CEO (website via YouTube)
February 10, 2023 07:30 AM EST
Deals
R&D

Oramed to re­view strate­gic al­ter­na­tives, cloud­ing path for­ward for oral in­sulin

Kyle LaHucik

Senior Reporter

Oramed Phar­ma­ceu­ti­cals will look at strate­gic al­ter­na­tives af­ter the biotech’s at­tempt at cre­at­ing an in­sulin pill fal­tered in a Phase III last month. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times